New eye injection shows promise for rare Blindness-Causing gene mutation
NCT ID NCT05902962
First seen Apr 17, 2026 · Last updated Jun 19, 2026 · Updated 9 times
Summary
This early-stage study tested a new drug, VP-001, given as an injection into the eye to see if it is safe for people with a rare genetic eye disease caused by a PRPF31 mutation. Seventeen adults took part. The main goal was to check for side effects, not to measure vision improvement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINAL DYSTROPHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Bascom Palmer Eye Institute University of Miami
Miami, Florida, 33136, United States
-
Baylor College of Medicine- Alkek Eye Center
Houston, Texas, 77030, United States
-
Oregon Health and Science University - Casey Eye Institute
Portland, Oregon, 97239, United States
-
Retina Foundation of the Southwest
Dallas, Texas, 75321, United States
-
University of Florida Health
Jacksonville, Florida, 32209, United States
-
University of Michigan Kellogg Eye Center
Ann Arbor, Michigan, 48105, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.